Enzo Biochem, Inc. (NYSE:ENZ) Q3 2021 Earnings Conference Call June 9, 2021 4:30 PM ET Company Participants Jeremy Feffer - Investor Relations Barry Weiner - Co-Founder and President David Bench - Chief Financial Officer Conference Call Participants Andrew D’Silva - B. Riley Securities & Company Brett Reiss - Janney Montgomery Scott Operator Greetings. Welcome to the Enzo Biochem Third Quarter 2021 Financial Results and Business Update. [Operator Instructions] Please note this conference is being recorded. ...

Enzo Biochem, Inc. (NYSE:ENZ) Q2 2021 Earnings Conference Call March 15, 2021 4:30 PM ET Company Participants Jeremy Feffer - Investor Relations Barry Weiner - Co-Founder and President David Bench - CFO Conference Call Participants Paul Knight - KeyBanc Keith Maher - Armistice Capital Operator Greetings. Welcome to the Enzo Biochem Second Quarter 2021 Financial Results and Business Update. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presenta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number 001-09974 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) | --- | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number 001-09974 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) | --- | ...

Enzo Biochem, Inc. (NYSE:ENZ) Q1 2021 Earnings Conference Call December 9, 2020 4:30 PM ET Company Participants Jeremy Feffer - LifeSci Advisors Barry Weiner - Co-Founder and President David Bench - Chief Financial Officer Conference Call Participants Kyle Mikson - Cantor Fitzgerald Thomas O - Evermore Global Paul Nouri - Noble Equity Operator Greetings, and welcome to the Enzo Biochem First Quarter 2021 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer ses ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-09974 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York 13-2866202 (State or ...

Enzo Biochem, Inc. (NYSE:ENZ) Q4 2020 Results Earnings Conference Call October 13, 2020 4:30 PM ET Company Participants Jeremy Feffer - Investor Relations Barry Weiner - Co-Founder and President David Bench - Chief Financial Officer Conference Call Participants Operator Greetings. And welcome to the Enzo Biochem, Inc. Fourth Quarter and Fiscal 2020 Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number 001-09974 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) | --- | -- ...

Scientists enabling Healthcare™ INVESTOR PRESENTATION JUNE 2020 0 Forward-Looking Statements | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses are dep ...

Enzo Biochem, Inc. (NYSE:ENZ) Q3 2020 Earnings Conference Call June 8, 2020 5:00 PM ET Company Participants Barry Weiner - President David Bench - Chief Financial Officer Operator Good afternoon, and welcome to the Enzo Biochem Inc. Fiscal Third Quarter 2020 Operating Results Conference Call. I will now read the company's Safe Harbor statements. Except for historical information, the matters discussed in this news release maybe considered forward-looking statements within the meaning of Section 27A of the S ...